Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Microbix Biosystems Inc T.MBX

Alternate Symbol(s):  MBXBF

Microbix Biosystems Inc. develops and commercializes biological and technological solutions for human health and wellbeing. It enables the commercialization of diagnostic assays by making a range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its segments include development, manufacturing and sales of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples and, and development and commercialization of novel and proprietary products or technologies, such as Kinlytic. Its Kinlytic urokinase is a biologic thrombolytic drug used to treat blood clots.


TSX:MBX - Post by User

Comment by lscfaon Nov 24, 2020 8:38pm
165 Views
Post# 31966848

RE:RE:YouTube Interview

RE:RE:YouTube Interview

$10 million ebitda x 10 / 161 million  = $0.62 /sh. That's why I said the analyst target of $1.40 is nuts.

 

 

Jun 20

 

Share

108,772,705

 

Warrants

23,284,552

Avg $0.36

Options

9,893,000

Avg $0.39

 

141,950,257

 

Conv debentures

19,565,217

$4.5 mil @$0.23

Non convert deb.

 

$2.5 mil

 

161,515,474

 

 




mercedesman wrote:

Thx. 

picking up where you left off....

if a $10M EBITDA , using a conservative multiple for a profitable Biotech of just 10X ...

...that's a $100M market cap ( vs today's .. $47M 

suggesting a share price of close to $1

After not insignificant insider buys this months, that was enough for me.  I'm in for the 2 to 3 bagger. 

the growth in revenue and profitability, if realized, will likely translate into a higher multiple - making a 4-5 bagger ( from here) quite possible! 

Any US attention would be icing on the cake! 
 

MM 



<< Previous
Bullboard Posts
Next >>